Pharmacotherapeutic agents in the treatment of methamphetamine dependence

Kirsten C. Morley*, Jennifer L. Cornish, Alon Faingold, Katie Wood, Paul S. Haber

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    68 Citations (Scopus)


    Introduction: Methamphetamine use is a serious public health concern in many countries and is second to cannabis as the most widely abused illicit drug in the world. Effective management for methamphetamine dependence remains elusive and the large majority of methamphetamine users relapse following treatment.

    Areas covered: Progression in the understanding of the pharmacological basis of methamphetamine use has provided us with innovative opportunities to develop agents to treat dependence. The current review summarizes relevant literature on the neurobiological and clinical correlates associated with methamphetamine use. We then outline agents that have been explored for potential treatments in preclinical studies, human laboratory phase I and phase II trials over the last ten years.

    Expert opinion: No agent has demonstrated a broad and strong effect in achieving MA abstinence in Phase II trials. Agents with novel therapeutic targets appear promising. Advancement in MA treatment, including translation into practice, faces several clinical challenges.

    Original languageEnglish
    Pages (from-to)563-578
    Number of pages16
    JournalExpert Opinion on Investigational Drugs
    Issue number5
    Publication statusPublished - 4 May 2017


    • Methamphetamine
    • pharmacotherapy
    • psychostimulant
    • substance use
    • treatment


    Dive into the research topics of 'Pharmacotherapeutic agents in the treatment of methamphetamine dependence'. Together they form a unique fingerprint.

    Cite this